Welcome to AntibioTx

AntibioTx is focused on developing novel antibiotic treatments to combat highly infectious diseases. We aim to create medicines that are safe and effective against multi-drug resistant pathogens with a clear purpose: Eliminating resistance to help patients.

"The greatest risk of hubris to human health comes in the form of antibiotic-resistant bacteria"- The World Economic Forum's Global Risks 2013

“Antimicrobial resistance is one of the three greatest threats to human health”- World Health Organization

AntibioTx receives funding from The Advanced Technology Foundation

AntibioTx receives funding from Novo A/S

Promising results against C. difficile

In vivo proof-of-concept against S. aureus

Promising results against P. acnes

AntibioTx receives grant from Innovation Fund Denmark

Final formulation of ATx201 shows promising human skin penetration

Promising results against MRSA


AntibioTx is a privately held pharmaceutical company dedicated to the development of a novel class of antibiotics to treat bacterial infections and related disorders that are currently causing harm to millions of patients worldwide.

AntibioTx has a fully operational lab and has utilized cutting edge systems biology and screening methods to identify and characterize a potential game changing class of antibiotics.


The mission of AntibioTx is to develop and commercialize groundbreaking antibiotics to overcome antibiotic resistance and fight infectious diseases. The need for novel antibiotics has been emphasized repeatedly as the evolution of antibiotic resistance continues. AntibioTx is committed to developing and marketing a portfolio of innovative antibiotics capable of addressing highly resistant infections and unmet medical needs.

The Class of AntibioTx

The AntibioTx-class is differentiated from current antibiotics in several ways:

  • The class effectively overcomes current resistance problems such as methicillin and vancomycin resistance
  • The class is based on a simple chemical scaffold that can be synthesized to target multiple indications
  • The class exhibits extraordinarily strong ability to delay the onset of de novo resistance
  • The class benefits from low risk due to decades of safe use for other types of diseases


Bacterial infections are a leading cause of death worldwide and the relentless evolution of antimicrobial resistance renders currently available antibiotics ineffective at an increasing pace. Recent studies estimate that by 2050, antibiotic resistance could lead to as many as 10 million mortalities annually and societal costs in excess of 100 trillion USD.

Antibiotic Resistance

Antibiotic resistance is a natural evolutionary phenomenon wherein bacteria prevent an antibiotic from working against an infection. Antibiotics and antimicrobial drugs have been used since the 1930’s to treat patients suffering from infectious diseases. However, due to their prolonged use, infectious organisms develop resistance towards antibiotics. Over the course of several years, improper use and misuse of antibiotics have led to a dramatic increase in the number of antibiotic resistant bacteria. Today, antibiotic resistance is an alarming global problem charged by the spread of bacteria across the world.

The reasons for the development of antibiotic resistance are complex and while most current antibiotics are on the verge of becoming ineffective against resistant strains of bacteria, very few efforts are being taken to develop newer and more effective antibiotics.

Over the past 40 years, only two new antibiotic classes have been brought to patients. Public healthcare systems and drug developers have been relying on analogues of existing antibiotics, but due to rapid emergence of renewed resistance to analogues of already challenged antibiotics, this approach has failed to address the threat from multi-drug resistance. To overcome this threat, new classes of antibiotics are needed.


AntibioTx has identified, characterized, and patent protected a new class of antibiotics. The class of antibiotics has broad applicability against pathogens and infections. Additionally, it is significantly de-risked due to decades of safe use for non-related purposes. AntibioTx has outlined a broader pipeline, but is currently focused on three lead candidates: ATx201, ATx202 and ATx401.


ATx201 – Topical treatment of bacterial skin infections

ATx201 has shown excellent potential against clinically relevant isolates of Staphylococus aureus including methicillin-resistant strains. Research shows that ATx201 confers a very low frequency of mutations and has shown outstanding antibacterial properties in animal models. Studies also reveal that ATx201 achieves high local concentrations at relevant human skin layers without any significant absorption of compound through the skin. ATx201 is a small molecule that is well characterized and has been used for human treatment for decades without ever being deployed for antibacterial purposes. AntibioTx have indications of mechanism of action, but additional work is required for a complete understanding. ATx201 is being developed for the topical treatment of bacterial skin infections.

  • Broad effect against relevant multi-drug resistant strains
    • Tested against strain panels comprising of relevant pathogens representing diverse profiles and recent clinical isolates
    • Displayed strong potency with no pre-existing resistant isolates
  • Non detectable de novo resistance
    • Plating assays demonstrated one-step resistant mutants did not form against ATx201
    • Serial passaging of 10 populations with ATx201 present over 21 days did not produce stable mutants with significantly increased MIC (<10x MIC)
  • Demonstrated in vivo effect
    • Tested extensively in mouse superficial skin infections model showing significant reduction in CFU counts
    • Various optimized formulations have confirmed reduction in bacterial counts
    • Presented equal potency against antibiotic sensitive strains to marketed topical formulations in short term experiments

ATx202 – Topical treatment of acne

ATx202 exhibits outstanding properties for the treatment of acne in terms of in vitro spectrum of effect and delayed onset of de novo resistance. Furthermore, the molecule has properties that are suitable for cutaneous delivery and long-term treatment which qualifies our belief that ATx202 can offer a superior treatment for more than 140 million patients in target countries who suffer from acne.

  • Low MIC values against relevant pathogens
  • Favorable physical and chemical properties
  • Reduced de novo resistance
  • Reduced risk due to previous human topical application for extended periods of time without any reportings of side effects
  • High concentrations achieved in relevant human skin layers

ATx401 – Oral treatment of Clostridium difficile

AntibioTx has identified a compound with strong effect against C. difficile. According to extensive microbiological characterization, ATx401 inhibits spore formation in C. difficile at a fixed level compared to the minimum inhibitory concentration.

  • Potent bactericidal antibiotic
  • Expected free concentration in feces orders of magnitude above MIC
  • Broad effect against vancomycin resistant enterococci
  • Reduction in germination and sporulation of C. difficile
  • Limited systemic exposure
  • Favorable safety profile

Market Opportunity

The global market opportunity for the three current pipeline priorities is in excess of 10 Billion USD annually and could potentially provide treatment to more than 200 million patients suffering for a variety of infectious and related diseases.

For each indication, there are significant unmet medical needs that represent a strong match with small molecule treatment and the characteristics of AntibioTx’s pipeline programs.


With a group of innovative employees, encompassing rich expertise in identification of new antibiotics and early stage development, AntibioTx is committed to improving the health of humans suffering from multidrug resistant infections.

Leadership Team

Rasmus Toft-Kehler, Chief Executive Officer

Rasmus has experience in business development from positions in a family enterprise, which was sold in 2005, management consulting at Booz Allen Hamilton and investment banking at Goldman Sachs and Gudme Raaschou.

Rasmus has a strong entrepreneurial inclination and has been involved with new ventures across a number of industries including co-founding two biotech companies.

Rasmus holds a degree in finance and business administration from Copenhagen Business School and New York University and an executive degree in entrepreneurial leadership from Harvard Business School.

Morten Sommer, Chief Scientific Officer

Morten Sommer is the founder of four biotech companies, including Microlytic founded in 2006 and serves over 150 customers, including 9 of the 10 largest pharmaceutical companies in the world. The company was sold in a cross-border transaction in 2015.

Morten is also a Professor at the Technical University of Denmark with a lab of 25 PhD's and Post docs working primarily in the field of antibiotic resistance. Morten is the inventor on 10+ issued patents, patent applications and author of scientific papers in journals such as Science and Nature.

Dr. Sommer holds a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.

Daniel Simon, Lead Scientist

Daniel has extensive experience with anti-infective research from academia and in leadership roles in the pharmaceutical industry. Before joining AntibioTx, Daniel was leading the Microbial Pathogenicity Laboratory at GSK and prior to that, he was the Head of Bacterial Genetics at Baxter Vaccine.

Daniel holds a Ph.D. in Microbiology from Paris Diderot University and has been an Assistant Professor in the Department of Microbiology and Immunology at Drexel University College of Medicine and an Assistant Professor in the Department of Microbiology and Immunology at Uniformed Services University of the Health Sciences.

Jan Trofast, PhD, Patent Strategist

Jan Trofast is the co-inventor of AstraZeneca’s blockbuster Symbicort, which is currently generating annual revenues of 4 Billion USD.

In addition to being an inventor, Jan is the strategist behind a highly successful patent portfolio of 25+ patents protecting Symbicort and related products. Symbicort is expected to become AstraZeneca’s best-selling drug despite core patent expiration.

Jan Trofast has more than 30 years of experience from AstraZeneca including a number of years with evaluation of internal and external projects. Jan Trofast obtained a Ph.D. in Organic Chemistry from Lund University in 1978.


AntibioTx constantly seeks like-minded and talented drug developers, scientists, and business developers at any level who share our passion for improving the health of humans suffering from multi-drug resistant infections.

We offer fast-paced, non-bureaucratic, merit-based career opportunities in a field with potentially life-saving results; applying deep knowledge of antibacterials, resistance mechanisms, cutting-edge advances in modern systems biology, microbiome insights, computational power and pharmaceutical expertise in a collaborative spirit to solve one of the greatest challenges of our time.

Please submit your motivation and CV to jobs@antibiotx.com if you are ready to eliminate resistance for a better human health.


Upcoming Events

  • January 10-15, 2016: JP Morgan (San Francisco)
  • February 22-26, 2016: Non-Deal Roadshow (Boston and New York)
  • April 9-12, 2016: ECCMID (Amsterdam)
  • April 11-16, 2016: Non-Deal Roadshow (New York and Boston)
  • June 6-9, 2016: BIO International (San Francisco)
  • June 16-20, 2016: Microbe (Boston)


Corporate Headquarters:

AntibioTx ApS
Kogle Allé 5
DK-2970 Hørsholm
Email: info@antibiotx.com
Phone: +45 61777435
CVR: 33963750

Investor and Media Relations:

The Ruth Group
Att. Tram Bui & Lee Roth
757 Third Avenue, Floor 26
New York, NY 10017
United States of America
Phone: +1 646-536-7035 / +1 646-536-7012
Email: tbui@theruthgroup.com / lroth@theruthgroup.com

Contact Us: